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RIFA B S T R A C T
Objectives: Drug-resistant tuberculosis (TB) is a major challenge in controlling TB. HIV-posi-
tive patients are vulnerable to TB 100 times more than the general population. Drug-resis-
tant TB leads to high morbidity and mortality in this population. In this study, the outcome
of treatment of drug-resistant TB among HIV positive patients from 2003 to 2013 in a ter-
tiary center in Iran will be reviewed.
Materials and methods: All HIV-positive patients with any drug-resistant TB from 2003 to
2013 were selected. The outcome of treatment was extracted from patients’ charts.
Results: Out of 269 TB-HIV patients, 34 patients were recruited. All patients were male and
the mean age was 37.38 ± 7.03. Isoniazid (INH) resistant, rifampin (RIF) resistant and multi-
drug resistant (MDR) was diagnosed in 11 (32.4%), 7 (20.6%) and 16 (47.1%), respectively.
Mean CD4 count was 91.61 ± 23.55. Outcome of treatment in the INH-resistant cases was
cured in 5 (45.5%), failure in 2 (18.2%) and death in 4 (36.4%). In the RIF-resistant group, out-
comewas as follows: cured 5 (71.4%) and failure in 2 (28.6%). In the MDR-TB patients’ group,
cured, failure and death were 12 (75%), 2 (12.5%) and 2 (12.5%), respectively.
Conclusion: Treatment of drug-resistant TB can be achieved despite considerable mortality.
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